MTOR and familial pancreatic carcinoma: It has been reported that MEK inhibitors, U0126 and PD0325901, abrogate BEZ235-induced (a PI3K/mTOR dual inhibitor) ERK activation in KRAS mutant pancreatic cancer cell lines [21].